New Target for Prostate Cancer Identified
The drug Gefitinib is used to treat breast, lung, and other cancers by inhibiting epidermal growth factor receptor (EGFR) signaling, but it has only a limited effect on prostate cancer. EGFR, present on the cell membrane, is involved in cell proliferation and the development of dermis, lung, and digestive tissues. When a mutation causes its over-activation, it can lead to increased cell proliferation and tumor formation.
Tadashi Matsuda of Hokkaido University and his colleagues in Japan investigated human prostate cancer cells to determine if there is an unknown up-regulation mechanism in the EGFR pathway.
When EGFR is attached to a small protein called ubiquitin, it is given “the kiss of death” and tagged for degradation inside the cell. This tagging process is facilitated by a protein called c-CBL. The degradation of EGFR leads to less signaling from the receptor and reduced cell proliferation.
Matsuda and his team found that signal-transducing adaptor protein-2 (STAP-2) stabilizes EGFR by inhibiting its c-CBL-mediated ubiquitination. Furthermore, when the team suppressed STAP-2, the prostate cancer cells showed reduced proliferation and did not form a tumor when transplanted into mice.
“STAP-2 inhibitors could play a role in treating Gefitinib-resistant prostate cancers. Further studies on STAP-2 will provide new insights into cancer physiology and support the development of anticancer therapies,” says Tadashi Matsuda. The study was published in the Journal of Biological Chemistry.
This article has been republished from materials provided by Hokkaido University. Note: material may have been edited for length and content. For further information, please contact the cited source.
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
A Mechanism of Drug Resistance in Breast & Ovarian CancerNews
Researchers have discovered the molecular means by which some cancers caused by errors in the gene BRCA1 evade treatment by drugs custom-tailored to kill them.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018